SHANGHAI HENLIUS BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.5 HKD | +0.98% |
|
+11.34% | +18.71% |
| Apr. 26 | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
| Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
Evolution of the average Target Price on Shanghai Henlius Biotech, Inc.
Price target over the last 5 years
History of analyst recommendation changes
1998988559c1227b28b48e503a1.OnxNCWAhpoa8hkx2veLzmZM_XaXSsHMZgPnXyUxPQL4.fgQ4SA9GkcD93xg49pOx0-l6BcSxhUcv85euoyoEFfZCSwNYLxLu05HzOw~adf02ca8839249cfd404954f2351a4f1
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.27
CNY
Average target price
16.39
CNY
Spread / Average Target
+7.30%
High Price Target
23.05
CNY
Spread / Highest target
+50.91%
Low Price Target
8.352
CNY
Spread / Lowest Target
-45.32%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- 2696 Stock
- Consensus Shanghai Henlius Biotech, Inc.
